ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Merus NV

Merus NV (2GH)

41.20
-1.00
( -2.37% )
Updated: 21:08:17
Realtime Data

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
41.20
Bid
39.60
Offer
40.40
Volume
248
41.00 Day's Range 42.80
21.40 52 Week Range 58.50
Previous Close
42.20
Open
42.80
Last Trade
20
@
41.2
Last Trade Time
21:01:45
Average Volume (3m)
127
Financial Volume
-
VWAP
-

2GH Latest News

Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC

Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC Studie mit Petosemtamab in Kombination mit Pembrolizumab bei 1L...

Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m

Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m...

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing...

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en fonction des données de sécurité et d’efficaci

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en...

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und Wirksamkeitsdaten aus der eNRGy-Studie bekannt

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und...

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts...

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive UTRECHT...

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 – Petosemtamab 1500 mg monotherapy phase 2 interim data continues to...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-4.8-10.434782608746474124844.22983871DE
4-10.3-2051.551.540.412544.72627361DE
12-4-8.8495575221245.251.540.412747.17167127DE
26-7.8-15.91836734694957.540.415948.54794972DE
5219.287.27272727272258.521.39999917544.36210739DE
15617.473.109243697523.858.51916742.00023485DE
26017.473.109243697523.858.51916742.00023485DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
2WOWide Open Agriculture Ltd
0.013 €
(85.71%)
35.39k
9SBSOL Global Investments Corp
0.38 €
(58.33%)
1.95M
2RY0China SXT Pharmaceuticals Inc
0.548 €
(55.02%)
6.1k
KEHChinese People Holdings Co Ltd
0.0045 €
(50.00%)
22.92k
NL8Genesis Ai Corp
0.0214 €
(40.79%)
3.95k
Y7GBioAge Labs Inc
5.65 €
(-70.26%)
2.02k
D4GDataMetrex AI Ltd
0.0034 €
(-41.38%)
135.5k
4APApollo Minerals Ltd
0.005 €
(-41.18%)
49.2k
HF2Reflex Advanced Materials Corp
0.0136 €
(-38.18%)
11.9k
NJF1Grid Metals Corp
0.016 €
(-37.25%)
2k
AXIAtos SE
0.0029 €
(3.57%)
626.95M
D7GNel ASA
0.2647 €
(0.84%)
1.97M
9SBSOL Global Investments Corp
0.38 €
(58.33%)
1.95M
3CPXiaomi Corporation
3.814 €
(5.68%)
1.84M
PF8European Lithium Limited
0.029 €
(-8.23%)
1.36M

Discussion

View Full Feed
exwannabe exwannabe 3 minutes ago
Progression-free Survival (PFS) was an INITIAL endpoint ...
PFS was the primary endpoint and used in the 2015 efficacy IA. Had it been a success they would have submitted for approval based on it many years ago. But the trial failed to establish the endpoint and the reason does not matter.
NWBO
LVerstee LVerstee 3 minutes ago
I thought you were https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175497600 not going to answer him?

Yes, they can all go to hell, the employees in India. I should sue them, for not paying me.
ITUP
SlamDunk89 SlamDunk89 3 minutes ago
Wayyyyyyy oversold.
RONN
Real McCoy Real McCoy 3 minutes ago
They reported every aspect of a lengthy restructuring attempt and ultimate liquidation though.
biocqr biocqr 4 minutes ago
Was up 20% then down 10% now no change...sheesh.
ENTA
rakp rakp 4 minutes ago
What's this company all about?
INFINITI INFINITI 7 minutes ago
Looking good for a rebound here $$$$$$$
RIME
sab63090 sab63090 8 minutes ago
Guzzi62

Thanks much, this was a very honest review in my opinion:

This is a major precipitous step because whatever funny business people may accuse a company of doing - and there have been a lot of such accusations here - an MAA brings everything under the spotlight.
AVXL
Energy Manager Energy Manager 8 minutes ago
A little food for thought from the DEA...

https://www.justthinktwice.gov/sites/default/files/2022-12/Impaired%20Driving%20Fact%20Card%20Web.pdf?utm_medium=email&utm_source=govdelivery
LCTC
Energy Manager Energy Manager 8 minutes ago
A little food for thought from the DEA...

https://www.justthinktwice.gov/sites/default/files/2022-12/Impaired%20Driving%20Fact%20Card%20Web.pdf?utm_medium=email&utm_source=govdelivery
LCTC
floblu14 floblu14 8 minutes ago
Monday, December 09, 2024 6:38:42 AM

Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)
Dec 09, 2024

Observed an antiviral effect for the p
ENTA
ksquared ksquared 9 minutes ago
Adam Schiff to Take Office Monday, Not in January, After Newsom Makes Power Play to Help California
JOEL B. POLLAK 8 Dec 2024 0:34

Representative Adam Schiff (D-CA) will become Senator Adam Schiff (D-CA) on Monday, December 9, after current Sen. Laphonza Butler (D-CA) resigne
FooBarAndGrill FooBarAndGrill 9 minutes ago
Sector is popping. $QBTS $RGTI $QUBT
QBTS RGTI
Risk vs Reward Risk vs Reward 11 minutes ago
Sells are 2:1 this am so far 
KULR
Debunkinator Debunkinator 11 minutes ago
$ASII--Let's have a barn burner of a week. 🚀 Past Due
ASII
Risk vs Reward Risk vs Reward 12 minutes ago
Somethings coming this week.... would be good timing after the pps cool down 
KULR
Reefrad Reefrad 12 minutes ago
I'm surprised you no longer bring up your "GBM" diagnosis. I guess you finally realized it if didn't really work so well with your agenda. Smart move. Then again, based on your incessant postings I would guess you might actually have had a frontal lobe or two resected. 
NWBO
floblu14 floblu14 13 minutes ago
Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)
Dec 09, 2024

Observed an antiviral effect for the primary and secondary virology endpoints in the overa
ENTA
biocqr biocqr 13 minutes ago
News out ENTA up 20%.

https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-announces-positive-topline-results-first

Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the
ENTA
Moonboy1 Moonboy1 16 minutes ago
What is this up so much? I don't see any news
GXAI
Streett Streett 17 minutes ago
Who owns the patent?  What we know for sure is that in the deal, if I have this right, HUMBL Pro is what remains in the HUMBL shell.  Everything else went to WSCG... correct?  The new company is bringing in a lot of product and if the SMX deal goes through, they will bring their own set of patents t
SMX
MasterBlastr MasterBlastr 17 minutes ago
I love Biden. He may not be a master politician, but he is a master of governing. He is setting things to run on autopilot while the Circus is in town.
Moonboy1 Moonboy1 19 minutes ago
All I know is I have shares and living it this morning
GXAI
dennisdave dennisdave 19 minutes ago
No one said they would look different "in the fall of this year". Innes said the company would like very different by THE END of this year.

Powers said this at last ASM:

It’s been longer than it was supposed to be (not shit), but all in all, I have to say, we’ve made, w
NWBO
TrendTrade2016 TrendTrade2016 22 minutes ago
ARE YOU STILL PRETENDING YOU ARE A WOMAN OR HAVE YOU COME OUT OF THE CLOSET MAGGOT
GVSI

Your Recent History

Delayed Upgrade Clock